Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Hospitalized Patients with COVID-19
NCT04421027Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Baricitinib + SOC with Placebo + SOC (2 arms). Primary endpoint: Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation at Day 28. Started Jun 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04421027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421027.